Commonwealth Equity Services LLC Has $212,000 Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Commonwealth Equity Services LLC reduced its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 63.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,600 shares of the biopharmaceutical company’s stock after selling 29,350 shares during the period. Commonwealth Equity Services LLC’s holdings in Dynavax Technologies were worth $212,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Dynavax Technologies in the 4th quarter valued at $71,000. Nisa Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares during the last quarter. Finally, KBC Group NV boosted its holdings in Dynavax Technologies by 68.7% in the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 2,857 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $12.03 on Thursday. The stock has a 50-day simple moving average of $13.28 and a 200 day simple moving average of $12.57. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The stock has a market capitalization of $1.49 billion, a PE ratio of 66.83 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.